OBJECTIVES: Complaints of fatigue are frequent in patients with obstructive sleep apnea (OSA); however, the impact of continuous positive airway pressure (CPAP) on fatigue remains unclear. METHODS:Fifty-nine men and women with OSA were randomly assigned to therapeutic or placebo CPAP in a double-blind fashion for a 3-week intervention period. Four outcome measures were assessed: (1) fatigue/vigor measured with the Multidimensional Fatigue Symptom Inventory--Short Form (MFSI-sf), the (2) fatigue and (3) vigor subscales of the Profile of Mood States--Short Form (POMS), and (4) the Epworth Sleepiness Scale (ESS). Data were analyzed using repeated-measures analysis of variance. RESULTS: Compared with patients receiving placebo CPAP, those patients treated with therapeutic CPAP showed significant reductions in the apnea-hypopnea index, as well as decreases in both measures of fatigue and increases in vigor (P values < 0.05). The beneficial effect of therapeutic treatment was most pronounced in patients with high levels of fatigue at study onset. Significant treatment effects in sleepiness scores were not observed in the entire sample (P > 0.05); however, in a subset of patients with excessive sleepiness at the onset of treatment, ESS scores were significantly reduced with use of therapeutic CPAP (P < 0.05). CONCLUSIONS: Results suggest that 3 weeks of therapeutic CPAP significantly reduced fatigue and increased energy in patients with OSA. Therapeutic CPAP significantly reduced daytime sleepiness in patients who reported excessive sleepiness at the onset of treatment.
RCT Entities:
OBJECTIVES: Complaints of fatigue are frequent in patients with obstructive sleep apnea (OSA); however, the impact of continuous positive airway pressure (CPAP) on fatigue remains unclear. METHODS: Fifty-nine men and women with OSA were randomly assigned to therapeutic or placebo CPAP in a double-blind fashion for a 3-week intervention period. Four outcome measures were assessed: (1) fatigue/vigor measured with the Multidimensional Fatigue Symptom Inventory--Short Form (MFSI-sf), the (2) fatigue and (3) vigor subscales of the Profile of Mood States--Short Form (POMS), and (4) the Epworth Sleepiness Scale (ESS). Data were analyzed using repeated-measures analysis of variance. RESULTS: Compared with patients receiving placebo CPAP, those patients treated with therapeutic CPAP showed significant reductions in the apnea-hypopnea index, as well as decreases in both measures of fatigue and increases in vigor (P values < 0.05). The beneficial effect of therapeutic treatment was most pronounced in patients with high levels of fatigue at study onset. Significant treatment effects in sleepiness scores were not observed in the entire sample (P > 0.05); however, in a subset of patients with excessive sleepiness at the onset of treatment, ESS scores were significantly reduced with use of therapeutic CPAP (P < 0.05). CONCLUSIONS: Results suggest that 3 weeks of therapeutic CPAP significantly reduced fatigue and increased energy in patients with OSA. Therapeutic CPAP significantly reduced daytime sleepiness in patients who reported excessive sleepiness at the onset of treatment.
Authors: Alexander Haensel; Daniel Norman; Loki Natarajan; Wayne A Bardwell; Sonia Ancoli-Israel; Joel E Dimsdale Journal: Sleep Breath Date: 2007-12 Impact factor: 2.816
Authors: Massimiliano M Siccoli; Justin C T Pepperell; Malcolm Kohler; Sonya E Craig; Robert J O Davies; John R Stradling Journal: Sleep Date: 2008-11 Impact factor: 5.849
Authors: Herbert J Yue; Wayne Bardwell; Sonia Ancoli-Israel; José S Loredo; Joel E Dimsdale Journal: Sleep Breath Date: 2009-03-25 Impact factor: 2.816
Authors: In-Soo Lee; Wayne A Bardwell; Rujvi Kamat; Lianne Tomfohr; Robert K Heaton; Sonia Ancoli-Israel; Jose S Loredo; Joel E Dimsdale Journal: Drug Discov Today Dis Models Date: 2011
Authors: Harneet K Walia; Sandra D Griffith; Nicolas R Thompson; Douglas E Moul; Nancy Foldvary-Schaefer; Reena Mehra Journal: J Clin Sleep Med Date: 2016-10-15 Impact factor: 4.062